BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 28753846)

  • 1. The Landscape of Whole-genome Alterations and Pathologic Features in Genitourinary Malignancies: An Analysis of the Cancer Genome Atlas.
    Ball MW; Gorin MA; Drake CG; Hammers HJ; Allaf ME
    Eur Urol Focus; 2017 Dec; 3(6):584-589. PubMed ID: 28753846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The germline mutational landscape of genitourinary cancers and its indication for prognosis and risk.
    Yang Y; Zhang G; Hu C; Luo W; Jiang H; Liu S; Yang H
    BMC Urol; 2022 Nov; 22(1):196. PubMed ID: 36451132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The molecular feature of macrophages in tumor immune microenvironment of glioma patients.
    Zhang H; Luo YB; Wu W; Zhang L; Wang Z; Dai Z; Feng S; Cao H; Cheng Q; Liu Z
    Comput Struct Biotechnol J; 2021; 19():4603-4618. PubMed ID: 34471502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
    Zhao S; Li Y; Xu J; Shen L
    Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advancing Pan-cancer Gene Expression Survial Analysis by Inclusion of Non-coding RNA.
    Ye B; Shi J; Kang H; Oyebamiji O; Hill D; Yu H; Ness S; Ye F; Ping J; He J; Edwards J; Zhao YY; Guo Y
    RNA Biol; 2020 Nov; 17(11):1666-1673. PubMed ID: 31607216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PreMSIm: An R package for predicting microsatellite instability from the expression profiling of a gene panel in cancer.
    Li L; Feng Q; Wang X
    Comput Struct Biotechnol J; 2020; 18():668-675. PubMed ID: 32257050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types.
    Guo B; Wang Y; Liu W; Zhang S
    Clin Transl Oncol; 2023 Feb; 25(2):535-554. PubMed ID: 36255654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A genomic mutation spectrum of collecting duct carcinoma in the Chinese population.
    Zhang H; Lu X; Huang G; Hua M; Zhang W; Wang T; Huang L; Wang Z; Chen Q; Li J; Yang Q; Yang G
    BMC Med Genomics; 2022 Jan; 15(1):1. PubMed ID: 34980126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Violations of proportional hazard assumption in Cox regression model of transcriptomic data in TCGA pan-cancer cohorts.
    Zeng Z; Gao Y; Li J; Zhang G; Sun S; Wu Q; Gong Y; Xie C
    Comput Struct Biotechnol J; 2022; 20():496-507. PubMed ID: 35070171
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Situ Y; Zhang J; Liao W; Liang Q; Lu L; Xu Q; Chen J; Lu X; Cui Y; Shao Z; Deng L
    Front Biosci (Landmark Ed); 2023 Sep; 28(9):196. PubMed ID: 37796681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive analysis of the novel omicron receptor AXL in cancers.
    Zhang WN; Li XP; Wang PF; Zhu L; Xiao XH; Dai YJ
    Comput Struct Biotechnol J; 2022; 20():3304-3312. PubMed ID: 35782741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. System analysis of
    Situ Y; Xu Q; Deng L; Zhu Y; Gao R; Lei L; Shao Z
    Int J Biol Markers; 2022 Mar; 37(1):90-101. PubMed ID: 34870494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrative omics analysis reveals relationships of genes with synthetic lethal interactions through a pan-cancer analysis.
    Guo L; Li S; Qian B; Wang Y; Duan R; Jiang W; Kang Y; Dou Y; Yang G; Shen L; Wang J; Liang T
    Comput Struct Biotechnol J; 2020; 18():3243-3254. PubMed ID: 33240468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Integrated Systematic Analysis and the Clinical Significance of Hepcidin in Common Malignancies of the Male Genitourinary System.
    Wang X; Shi Q; Gong P; Zhou C; Cao Y
    Front Genet; 2022; 13():771344. PubMed ID: 35646093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value and potential subtypes of immune activity scores in three major urological cancers.
    Shi B; Qi J
    J Cell Physiol; 2021 Apr; 236(4):2620-2630. PubMed ID: 32853461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive analysis of tumor necrosis factor-α-inducible protein 8-like 2 (TIPE2): A potential novel pan-cancer immune checkpoint.
    Bai KH; Zhang YY; Li XP; Tian XP; Pan MM; Wang DW; Dai YJ
    Comput Struct Biotechnol J; 2022; 20():5226-5234. PubMed ID: 36187930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CTHRC1 Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Kidney Renal Papillary Cell Carcinoma and Kidney Renal Clear Cell Carcinoma.
    Zhou F; Shen D; Xiong Y; Cheng S; Xu H; Wang G; Qian K; Ju L; Zhang X
    Front Oncol; 2020; 10():570819. PubMed ID: 33628726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rewired functional regulatory networks among miRNA isoforms (isomiRs) from let-7 and miR-10 gene families in cancer.
    Liang T; Han L; Guo L
    Comput Struct Biotechnol J; 2020; 18():1238-1248. PubMed ID: 32542110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.